Ïû»¯ÏµÍ³Ö×Áö/²¡Àíѧ,digestive system neoplasms/pathologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ä¶¾ËØ»ùÒò,Melittin geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Îøµ°°×P,selenoprotein PÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« MC,Mass customizationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÃâÒßÕ³¸½,immune adherenceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁÙ´²ÉúÎïѧÐÐΪ,Clinical biological behaviorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« EGFRÒÖÖÆ¼Á,EGFR inhibitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Éñ¾­ÄÚ·ÖÃÚÁö,Neuroendocrine TumorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾­À¨Ô¼¼¡Í¾¾¶,Transsphincteric ApproachÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÇòÐÎÌå,coccoid formÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Á×µ°°×Á×Ëáø,phosphoprotein phosphataseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ºÚ¼¬Æ¤²¡,acanthosis nigricansÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½á³¦Ö×Áö/²¡Àíѧ,colonic neoplasms/pathologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« DAPK»ùÒò,DAPK geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁªºÏÔàÆ÷Çгý,multivisceral resectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒÈÏÙÖ×Áö/ÖÎÁÆ,Pancreatic Neoplasms/therÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÎǺϿڳöѪ,anastomotic bleedingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ȫϵĤÇгý,Total mesorectal excisionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« VEGFmRNA,VEGF mRNAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸Î×ªÒÆÁö,Hepatic metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« DixonÊÖÊõ,dixon operationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·úÄòà×à¤/ͶҩºÍ¼ÁÁ¿,fluorouracil/administration & dosageÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« NK4»ùÒò,NK4 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Æô¶¯Çø,promoterÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁÙ´²²¡Àí·ÖÎö,Clinicopathologic analysisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µç×Ó¼ÆËã»úÌå²ãÉãÓ°,Computed tomographyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« É¢·¢ÐԴ󳦰©,Sporadic colorectal cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸¹Ä¤Ö×Áö,Peritoneal neoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°û¶¾ËØÏà¹Ø»ùÒòA,Cytotoxin associated gene AÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ³É±¾-ЧÓ÷ÖÎö,Cost-Utility analysisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½éÈëÐÔÈÈ»¯ÁÆ,Interventional heated chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾­Æ¤¾­¸Îµ¨¹ÜÒýÁ÷Êõ,Percutaneous transhepatic cholangial drainageÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« BxPC-3ϸ°û,BxPC-3 cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖÖϵͻ±ä,germline mutationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ƽ°å¿Ë¡Ðγɷ¨,Colony-forming assayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« MAD2»ùÒò,MAD2 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×éÖ¯¶àëÄ¿¹Ô­,Tissue polypeptide antigenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼¡´¼ÁùÁ×Ëá,inositol hexaphosphateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ѫ¹ÜÇгý,Vascular resectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Caveolin-1»ùÒò,Caveolin-1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö°©ÐÔÊÔÑé,carcinogenicity testsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼×Ì¥µ°°×ÒìÖÊÌå,alpha-fetoprotein variantÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÚ¾µÉ¸²é,Endoscopic screeningÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ÎÖ×Áö/Á÷Ðв¡Ñ§,liver neoplasms/epidemiologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Êõǰ·Å»¯ÁÆ,preoperative radiochemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸´·¢°©,Recurrent cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±£ÁôÅèÇ»×ÔÖ÷Éñ¾­,Pelvic autonomic nerve preservationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« E-cadherin»ùÒò,E-cadherin geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´Èµ¤½ºÄÒ,Cidan capsuleÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁܰÍÉÏÆ¤ÁöÑù°©,lymphoepithelioma-like carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« DNAËðÉË¼ì¿Øµã,DNA damage checkpointÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« EGFRµ°°×,EGFR proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁܰͽáÇå³ýÊõ,Lymph node dissectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ԭʼÉñ¾­ÍâÅß²ãÁö,primitive neuroectodermal tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« TGF¦Â1»ùÒò,TGF¦Â1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐòÁÐȱʧ,sequence deletionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« È©ÍÑÇâø,Aldehyde dehydrogenaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ý¼ÌÃâÒßÁÆ·¨,adoptive immunotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹Ü״θ,gastric tubeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ³ÖÐøµÎ×¢,continuous infusionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½ª»ÆËØ¢ó,curcumin ¢óÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö±³¦Àà°©,Rectal carcinoidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´ÅÁ÷ÌåÈÈÁÆ,magnetic fluid hyperthermiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« DNA¸Éϵ±¶Ìå,DNA stemline ploidyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ïû»¯ÏµÍ³Ö×Áö/Ò©ÎïÁÆ·¨,digestive system neoplasms/drug therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ô­·¢ÐÔθÁܰÍÁö,Primary gastric lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½»½çÐÔÖ×Áö,borderline tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« GTP½áºÏµ°°×,GTP-binding proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·°»¯ÄÆ,sodium vanadateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸¹Ç»¾µ¸ÎÇгýÊõ,laparoscopic hepatectomyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾­µ¼¹Ü¶¯Âö»¯ÁÆË¨Èû,Transcatheter arterial chemoembolizationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Éñ¾­ÍøÂç(¼ÆËã»ú),neural networks(computer)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÉÃ×·Ðʯ,nanosized zeoliteÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÅÉäÕï¶Ï,Diagnostic RadiologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼Ò×åÐÔθ°©,familial gastric cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Lewis¿¹Ô­,Lewis antigenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« PANC-1ϸ°û,PANC-1 cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Á¢ÌåÊÊÐηÅÉäÖÎÁÆ,Three-dimensional conformal radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄñÜÕËá»·»¯Ã¸,guanylate cyclaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÔçÆÚ´ó³¦°©,early colorectal carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Âѳ²½»½çÐÔÖ×Áö,Borderline ovarian tumorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« MLH1»ùÒò,MLH1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ʵÐÔ¼ÙÈéÍ·×´Áö,Solid pseudopapillary tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈËθ°©Ï¸°û,Human gastric carcinoma cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÌÇÁ´¿¹Ô­19-9,carbohydrate antigen 19-9Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ²ãð¤Á¬µ°°×ÊÜÌå,laminin receptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ʳ¹ÜÖ×Áö/Íâ¿ÆÊÖÊõ,Esophageal neoplasms/surgeryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ËÁ£Ã¸´ß»¯Ñǵ¥Î»,hTERTÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« HBV X»ùÒò,HBV X geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÚ¾µÕï¶Ï,Endoscopic diagnosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶àϸ°ûÄÍÒ©,multicellular resistanceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼äÒ¶ÐÔÖ×Áö,Mesenchymal tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Notch1»ùÒò,Notch1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖÜÆÚËØÒÀÀµ¼¤Ã¸ÒÖÖÆ¼Áp27,Cyclin-Dependent Kinase Inhibitor p27Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« »ºÊÍ»¯ÁÆ,Sustained-release chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ð¤ÒºÏÙ°©,mucinous carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« H22ϸ°ûÖê,H22 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Äý¹ÌÐÔ»µËÀ,Coagulative necrosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ô­·¢ÐÔ¸Îϸ°û¸Î°©,primary hepatocellular carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸Î¶¯¾²Âöðü,Hepatic arteriovenous fistulaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«